Ranbaxy Laboratories (Ranbaxy) announced today that the world health organization, Geneva (WHO), has included the company`s Indinavir (as sulfate) - 400mg anti retroviral capsule, in its pre-qualification list.

With this new addition, Ranbaxy (Q,N,C,F)* now has a total of 19 ARVs on the WHO prequalification list.

Commenting on the WHO listing, Ranhaxy`s chief executive officer (CEO) and managing director (MD), Atul Sobti said, `` Ranbaxy remains committed to provide high quality affordable generic ARV medicines and will continue to dedicate itself in lighting the worldwide struggle against HIV/AIDS. ``

Ranbaxy`s ARVs, including the recently approved WHO`s pre-qualified products, are manufactured at its state of art manufacturing facilities.

Since 2001, Ranbaxy has been providing high quality ARV medicines, at affordable prices , in over 70 markets worldwide, thereby facilitating access to patients afflicted by HIV/AIDS who might not, otherwise have been able to gain access to this therapy its  ARVs have been used as mainstays in various large treatment programs, both national and NGO / institutional with good results ARV medicine produced by Ranbaxy are used by over 400,000 patients worldwide , in various developing and underdeveloped countries.

Ranbaxy is committed to supporting the global fight against HIV/ AIDS through high quality, affordable medicines.

Shares of the company declined Rs 4.45, or 1.07%, to settle at Rs 412.30. The total volume of shares traded was 191,618 at the BSE (Thursday).